Zacks Investment Research Downgrades Lorus Therapeutics (APTO) to Hold
Zacks Investment Research downgraded shares of Lorus Therapeutics (NASDAQ:APTO) (TSE:APS) from a buy rating to a hold rating in a research note issued to investors on Monday.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
Other research analysts have also issued reports about the stock. Roth Capital set a $6.00 target price on shares of Lorus Therapeutics and gave the company a buy rating in a research note on Monday. HC Wainwright set a $6.00 price target on shares of Lorus Therapeutics and gave the company a buy rating in a report on Monday. Finally, ValuEngine raised shares of Lorus Therapeutics from a strong sell rating to a sell rating in a report on Tuesday, April 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $5.63.
A hedge fund recently raised its stake in Lorus Therapeutics stock. Acadian Asset Management LLC lifted its holdings in shares of Lorus Therapeutics, Inc. (NASDAQ:APTO) (TSE:APS) by 316.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the period. Acadian Asset Management LLC owned approximately 0.17% of Lorus Therapeutics worth $100,000 as of its most recent filing with the SEC. 1.17% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/04/17/zacks-investment-research-downgrades-lorus-therapeutics-apto-to-hold.html.
About Lorus Therapeutics
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lorus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lorus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.